Barrett's esophagus is a very common premalignant lesion affecting between 2-3% of the adult population in the West. As a consequence strategies have evolved to attempt to abrogate the progression along the metaplasia-dysplasia-adenocarcinoma sequence. Several strategies including earlier detection, screening and surveillance have an unproven efficacy. As a consequence the role of chemoprevention agents (drugs which can prevent cancer) has come to the fore. The prime agent is aspirin but the risk-benefit ratio remains unclear. In addition it isn't clear who will respond best and who will be destined for life threatening complications. Genomics may be able to tease this out.
The International Society for Diseases of the Esophagus is a 501(c)3 non-profit organization.
General Inquiries: email@example.com
Membership Questions: firstname.lastname@example.org